CURAPOD, a health tech startup, has received ₹20 crore (about $2.2 million) in a pre-Series A funding round. V3 Ventures, 3i Partners, and Ideaspring Capital led the round. Litemed also supports the company, showing investors are confident in CURAPOD’s tech and clinician-led way to deal with muscle and bone issues in India’s growing Direct-to-Consumer health tech market.
Sri Velliyur and Surya Maguluri started CURAPOD in 2022. It’s making wearable, non-invasive pain solutions for everyday use. As Indian D2C news focuses more on health, CURAPOD stands out because it offers a drug-free option for pain. This meets the rising need for safer, lasting answers for long-term muscle and bone problems caused by lifestyle.
The ₹20 crore will help CURAPOD speed up its research and build a better device and app. It will also help them make more products and improve how they sell them. A big goal is to grow the brand’s online presence and team up with gyms, physical therapy centers, and sports medicine groups. These online growth plans fit with D2C market trends for 2025, where health tech brands mix doctor approval with easy access for customers to build trust and get repeat business.
CURAPOD’s main wearable device uses photobiomodulation therapy, a non-invasive way to ease pain and swelling while helping tissues heal. The FDA has registered the device, and it can help with over 30 muscle and bone conditions, like back pain, neck pain, knee pain, joint problems, stiff muscles, and sports injuries. This makes CURAPOD one of the newest D2C startups using approved medical tech to create reliable health brands for customers in India’s changing D2C world.
Unlike wellness products that just focus on consumers, CURAPOD uses a doctor-led model. They work with health experts to prove results and guide how people use the product. This shows a bigger change in India’s D2C business, where trust, medical proof, and real results are becoming key to building brand stories, especially in health, wellness, and prevention.
As muscle and bone problems from lifestyle get worse because of sitting too much, intense fitness, and getting older, CURAPOD is aiming for a big market that isn’t fully served. They have a tech solution that fits easily into daily life. The company’s plans to make things work better and strengthen its manufacturing and delivery show they want to grow slowly and responsibly instead of quickly and unsustainably.
The pre-Series A round also shows that D2C is funding health tech brands that combine devices, software, and medical approval again. As VC-backed D2C brands move past things like makeup and vitamins into approved health areas, CURAPOD’s progress shows how India’s D2C industry news is changing because of creative, clinically-based startups.
With new funds, strong investor support, and a growing reach across the country, CURAPOD is in a good spot to become a key player in India’s drug-free pain market. As Direct-to-Consumer India keeps moving toward health solutions with real results, CURAPOD’s focus on tech, trust, and access puts it among the fastest-growing D2C health tech brands to watch.
